King Minos hall III
King Minos hall III
General assembly
Διαλειμα - Καφές
Clinical Nephrology
N.3B. Renal dietetics
1. TBC
2. TBC
3. TBC
A. Γόμπου, Δ. Κιρμιζής
Β. Σταθόπουλος
N.3B. Renal dietetics
1. TBC
2. TBC
3. TBC
Δικηγόρος Ιασώ
Διαλειμμα - Καφές
Διαλειμμα - Γεύμα
Clinical Nephrology
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL Dimitrios Bakoulis
2. New and emerging therapies in IgA nephropathy Panagiotis Kompotiatis
3. How should I manage the patient with IgA nephropathy Maria Stangou
Κ. Ψούνης,
Ε. Φράγκου / Β. Αθανασιάδου
Ι. Στεφανίδης
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL Dimitrios Bakoulis
2. New and emerging therapies in IgA nephropathy Panagiotis Kompotiatis
3. How should I manage the patient with IgA nephropathy Maria Stangou
Θ. Χήρας
Γ. Μυσερλής
Ν. Αντωνιάδης
Δ. Κιρμιζής / Β. Αθανασιάδου
Διαλειμμα - Καφές
Cardiovascular morbidity
Ε. Ιντζεβίδου
Ι. Δρούλιας
N.6A. Hypertension
1. Management of hypertension in patients with CKD Georgios Hatzivasiliou
2. Resistant hypertension Vasileios Raptis
3. Use of diuretics in CKD: benefits and risks Eleni Intzevidou
4. Hypertension in dialysis Antonios Zagorianakos
Βαρέτα / Π. Νέννες, Η. Κυρίτσης
Cardiovascular morbidity
N.7A. Haemodialysis
1. Uremic pruritus: systematic review, evaluation and management Olga Ellina
2. Response to ultrafiltration in dialysis Nikolaos Mitsides
3. Management of the patient with diabetes on dialysis Irini Vasiliou
Π. Μανωλακάκη
Γ. Βολιώτης
Ν. Ζουμπαρίδης
Λ. Πόσα, K. Παπακωστούλα
Cardiovascular morbidity
Π. Μακρή
N.3A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new? Ioannis Droulias
2. HIF inhibitors: their place in clinical practice Athena Gompou
3. Update in the management of hyperkalaemia Evdokia Efthymiou
Λ. Ποτόλια / Βαρέτα
Δ. Μωϋσιάδης
Ε. Σταυρινού
Close
Approved by:
Accreditation: